New drug could help High-Risk patients get Life-Saving transplants

NCT ID NCT06398457

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant to proceed. Participants receive the drug before standard transplant preparation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia adult acute lymphoblastic leukemia aplastic anemia chronic myelogenous leukemia, BCR-ABL1 positive hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hodgkins lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive lymphoma myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ADULT ACUTE MYELOID LEUKEMIA (AML) APLASTIC ANEMIA BONE MARROW TRANSPLANT REJECTION CHRONIC MYELOID LEUKEMIA HEMATOLOGIC MALIGNANCY HODGKIN LYMPHOMA LYMPHOMA MULTIPLE MYELOMA MYELODYSPLASTIC SYNDROMES (MDS) MYELOFIBROSIS NON HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITING

Baltimore, Maryland, 21231, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••